KPMG Australia Cuts 5% of Workforce Amid Scandal 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
California Seeks Paramount Divestitures in Warner Bros. Merger 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
Ampol Profit Surges as Refining Margins Hit Record Highs 
Nvidia Options Price in $280 Billion Earnings Swing 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
Add as a preferred source on Google
REDWOOD CITY, Calif., May 01, 2018 -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that senior management will be presenting at the Bank of America Merrill Lynch Health Care Conference on Wednesday, May 16, 2018 at 11:40 am ET being held in Las Vegas, Nevada.
The audio portion of the presentation will be available on the investors page of the Coherus BioSciences website at http://investors.coherus.com.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-1420 (adalimumab biosimilar) and CHS-0214 (etanercept biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology including CHS-3351 (ranibizumab biosimilar) and CHS-2020 (aflibercept biosimilar), and CHS-131, a small molecule for multiple sclerosis. For additional information, please visit www.coherus.com.
CONTACT:
Patrick O'Brien
Senior Vice President, Investor Relations
Coherus BioSciences, Inc.
[email protected]
+1 (650) 649-3527
